Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Apixaban tied to lower VTE rate, higher bleeding risk in cancer

Carrier M et al. N Engl J Med. 2018 Dec 4. doi: 10.1056/NEJMoa1814468

Key clinical point: Apixaban lowered the rate of venous thromboembolism to 4.2% in patients with cancer, half the rate seen in similar patients given placebo.

Major finding: The number needed to treat to prevent 1 venous thromboembolism was 17.

Study details: A placebo-controlled, double-blind, randomized trial in 574 cancer patients.

Disclosures: The study was supported by the Canadian Institutes of Health Research and Bristol-Myers Squibb–Pfizer Alliance. Thirteen authors declared honoraria, grants, or personal fees from the pharmaceutical industry unrelated to the study. Two declared grants from the study funders for the study; ten authors had no conflicts of interest to declare.

Read the article here.

Citation:

Carrier M et al. N Engl J Med. 2018 Dec 4. doi: 10.1056/NEJMoa1814468.